{"id":23541,"date":"2024-01-22T10:50:00","date_gmt":"2024-01-22T09:50:00","guid":{"rendered":"https:\/\/idibell.cat\/en\/?p=23541"},"modified":"2024-01-22T13:40:02","modified_gmt":"2024-01-22T12:40:02","slug":"the-ministry-of-science-and-innovation-awards-e4-million-for-the-phase-2b-clinical-trial-with-a-new-drug-for-ischemic-stroke","status":"publish","type":"post","link":"https:\/\/idibell.cat\/en\/2024\/01\/the-ministry-of-science-and-innovation-awards-e4-million-for-the-phase-2b-clinical-trial-with-a-new-drug-for-ischemic-stroke\/","title":{"rendered":"The Ministry of Science and Innovation awards \u20ac4 million for the Phase 2b clinical trial with a new drug for ischemic stroke"},"content":{"rendered":"
The consortium formed by aptaTargets<\/strong>, the Bellvitge Biomedical Research Institute<\/a> (IDIBELL), the Germans Trias i Pujol Research Institute<\/a> (IGTP), the University of Valladolid<\/a> and the Vall d’Hebron Research Institute<\/a> (VHIR) has received \u20ac4 million in funding from the Spanish Ministry of Science and Innovation through the State Research Agency<\/a> (AEI).<\/p>\n <\/p>\n The grant will support the NexTOLL project<\/strong>, which aims to launch a multicentre Phase 2b clinical trial to confirm the neuroprotective effect of ApTOLL<\/strong> in patients with acute ischemic stroke<\/strong> (AIS). The clinical trial is scheduled to start in 2024 and Pere Cardona, Principal Investigator at the Neurologic Diseases and Neurogenetics research group<\/a> at IDIBELL and Director of Neurovascular Program and Stroke Unit<\/a> at the Bellvitge University Hospital, will be among the neurologists conducting it.<\/p>\n <\/p>\n These funds come from a highly competitive call for proposals from the State Programme for the Promotion of Scientific and Technical Research and its Transfer 2022 (formerly known as Retos Colaboraci\u00f3n<\/em>) which provides funding for public-private collaboration projects to catalyse innovation and business leadership in small and medium-sized enterprises (SMEs).<\/p>\n <\/p>\n Notably, the results of the research conducted with ApTOLL to date are very encouraging. ApTOLL is the first neuroprotective drug to obtain positive results in clinical trials<\/a> with patients, which were presented at the International Stroke Conference 2023 and published in the prestigious scientific journal JAMA Neurology<\/em><\/a>. <\/em><\/p>\n <\/p>\n The funding received from the AEI is key to bringing ApTOLL to the market<\/strong>, which could provide an important therapeutic option for stroke patients who have a significant unmet medical need.<\/p>\n \u00a0<\/em><\/p>\n A Phase IIb Clinical trial to the evaluate neuroprotective effect of ApTOLL in stroke patients. <\/em>NexTOLL CPP2022-<\/em>009778.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":" Collaborative success in advancing stroke neuroprotection<\/p>\n","protected":false},"author":8,"featured_media":23542,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[239,301,188],"tags":[],"class_list":["post-23541","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-neurologic-diseases-and-neurogenetics","category-neuroscience-area","category-neuroscience-program"],"publishpress_future_action":{"enabled":false,"date":"2024-11-28 16:15:45","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/posts\/23541","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/comments?post=23541"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/posts\/23541\/revisions"}],"predecessor-version":[{"id":23543,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/posts\/23541\/revisions\/23543"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/media\/23542"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/media?parent=23541"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/categories?post=23541"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/tags?post=23541"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}